Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world
Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions.
ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early data on VH184 and VH499 therapies.
For the current year, BioNTech projected revenue of 1.7 billion euros to 2.2 billion euros, below the market consensus of 2.54 billion euros and a fall from last year's 2.75 billion euros.
Over the past six months, Pfizer’s shares (currently trading at $26.70) have posted a disappointing 10.2% loss, well below the S&P 500’s 3.8% gain. This might have investors contemplating their next move.
Sen. Elizabeth Warren and other lawmakers raised concerns about Robert F. Kennedy Jr.'s private dinners with pharmaceutical executives at Mar-a-Lago, questioning his commitment to reducing corporate influence as Secretary of Health and Human Services.
BioNTech's Q4 revenue beat estimates despite lower COVID-19 vaccine sales. The company advances oncology programs, with key data updates expected in 2025.
Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Monday and uncover the stocks that are leading the way in terms of trading volume and market attention.
In light of potential tariff threats from President Donald Trump, Pfizer Inc.'s (PFE.N) CEO Albert Bourla has suggested the possibility of shifting the company's overseas manufacturing to its U.S. facilities.
Over the past six months, Zoetis’s shares (currently trading at $166) have posted a disappointing 9.6% loss, well below the S&P 500’s 7.6% gain. This was partly driven by its softer quarterly results and might have investors contemplating their next move.
